The Lancet Neurology in conversation with
Podcast tekijän mukaan The Lancet Group - Torstaisin
187 Jaksot
-
Giuseppe Citerio on frailty and TBI
Julkaistiin: 19.1.2022 -
Alberto Costa on memantine in adolescents and young adults with Down syndrome
Julkaistiin: 20.12.2021 -
Olivier Rascol on amantadine for patients with movement disorders
Julkaistiin: 17.11.2021 -
Antonio Uccelli on stems cells for MS
Julkaistiin: 20.10.2021 -
Priya Palta on blood pressure control and cognitive decline
Julkaistiin: 15.9.2021 -
Adam Boxer on tau biomarkers
Julkaistiin: 18.8.2021 -
Irene Cortese on the difficulties of designing clinical trials
Julkaistiin: 21.7.2021 -
Doug Turnbull on mitochondrial diseases in adults
Julkaistiin: 16.6.2021 -
Geert Jan Biessels on predicting post-stroke cognitive impairment
Julkaistiin: 19.5.2021 -
Henk-Jan Westeneng on the causal effects of pre-symptomatic lifestyle on ALS
Julkaistiin: 21.4.2021 -
Anne MacGregor on menstrual migraine
Julkaistiin: 17.3.2021 -
Peter Rothwell on asymptomatic carotid stenosis and stroke
Julkaistiin: 17.2.2021 -
Spinal cord injury and degenerative cervical myelopathy
Julkaistiin: 20.1.2021 -
Genetic risk factors for sCJD
Julkaistiin: 22.12.2020 -
Prednisone in short-term prevention of cluster headache
Julkaistiin: 24.11.2020 -
PET imaging of inflammation in neurological and psychiatric disorders
Julkaistiin: 21.10.2020 -
Neurological associations of COVID-19
Julkaistiin: 4.9.2020 -
Advances in understanding of Rett syndrome
Julkaistiin: 31.7.2020 -
Management of Parkinson's disease
Julkaistiin: 17.6.2020 -
Optimal time to treat Huntington's Disease
Julkaistiin: 26.5.2020
Editors at The Lancet Neurology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.A monthly audio companion to the journal, this podcast covers a broad range of topics, from sleep habits to amyloid biomarkers in Alzheimer’s, the diagnosis and classification of optic neuritis to treatment of Creutzfeldt-Jakob disease, and more.
